Drug General Information
Drug ID
D0OZ7P
Former ID
DNC002375
Drug Name
BILN-2061
Drug Type
Small molecular drug
Indication Hepatitis virus infection [ICD9: 573.3; ICD10:K75.9] Phase 2 [524893]
Therapeutic Class
Antiviral Agents
Structure
Download
2D MOL

3D MOL

Formula
C40H50N6O8S
Canonical SMILES
CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)OC4CC5C(=O)<br />NC6(CC6C=CCCCCCC(C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O
InChI
1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1
InChIKey
PJZPDFUUXKKDNB-KNINVFKUSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Nonstructural protein NS3 Target Info Inhibitor [536050]
References
Ref 524893ClinicalTrials.gov (NCT02226939) Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C. U.S. National Institutes of Health.
Ref 536050Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.